Evidence map›Paper›PMID 36494701›Full record

ArticleCancer cell international2022

Potential of Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, as a hot tumor inducer.

Takayuki Horii, Yuki Orikawa, Yuta Ohira, Runa Eta, Nobuyoshi Kobayashi, Takanori Sato, Takeshi Watanabe, Takao Tanaka

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Takayuki HoriiCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya, Saitama, 360-0111, Japan. takayuki-horii@zeria.co.jp.ORCID http://orcid.org/0000-0001-7349-2147
Yuki OrikawaCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya, Saitama, 360-0111, Japan.
Yuta OhiraCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya, Saitama, 360-0111, Japan.
Runa EtaCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya, Saitama, 360-0111, Japan.
Nobuyoshi KobayashiCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya, Saitama, 360-0111, Japan.
Takanori SatoCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya, Saitama, 360-0111, Japan.
Takeshi WatanabeCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya, Saitama, 360-0111, Japan.
Takao TanakaCentral Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Numagami, Oshikiri, Kumagaya, Saitama, 360-0111, Japan.
Zeria Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment is one of the most important factors determining the efficacy of cancer immunotherapy. In particular, variability in efficacy has been linked to whether tumors are hot or cold, with hot tumors exhibiting greater T cell infiltration and responding better to immunotherapy. Z-100 extracted from Mycobacterium tuberculosis Aoyama B strain has been reported to increase cytokine production from immune cells. In this study, we examined its effect on the tumor microenvironment and its potential as a hot tumor inducer. The antitumor effect of Z-100 was confirmed in a mouse oral squamous cell carcinoma (Sq-1979) tumor model by starting administration before tumor injection. Treated tumors were collected to identify infiltrating CD8

Indexed as

Antitumor effectCD8+ T cellHot tumorIL-12Tumor-infiltrating lymphocytes

Identifiers

PMID36494701
PMCPMC9733245
OpenAlexW4311503882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.